ACRPO  >> Vol. 6 No. 1 (January 2017)

    Analysis of the Efficacy of Apatinib in the Treatment of Brain Metastases of Lung Adenocarcinoma

  • 全文下载: PDF(640KB) HTML   XML   PP.1-8   DOI: 10.12677/ACRPO.2017.61001  
  • 下载量: 1,052  浏览量: 3,624  


祝金龙,王 红:解放军第307医院肺部肿瘤科,北京

甲磺酸阿帕替尼非鳞非小细胞肺癌晚期肺癌Apatinib Non-Small-Cell Lung Cancer Advanced Lung Cancer



Lung cancer is one of the world’s most common and most malignant tumors. The lethality rate of which is the highest in all types of malignant tumors. The five-year survival rate of it is less than 20%, non-small cell lung cancer accounting for more than 70% of all cases and being diagnosed in the locally advanced stage. The 5-year survival rate of NSCLC is less than 6%. Patients can get relief and survival benefit by chemotherapy. Most patients will get PD in 2 or 3 months after the last chemotherapy, especially for those with negative genetic testing showing dismal efficacy to the application of molecular targeted drugs. Study found that neovascularization provide oxygen and nutrition for the growth of the tumor, to promote its growth. Anti-angiogenic drugs can inhibit tumor from progressing and metastasis by inhibiting angiogenesis. And the vascular epidermal growth factor (VEGF) can activate the downstream pathway to stimulate the proliferation of vessel endothelium via binding vascular epidermal growth factor receptor (VEGFR), thus leading to the growth of tumor. Paclitaxel mesylate is a small molecular anti-angiogenesis inhibitor. It can inhibit solid tumor growth factor tyrosine kinase receptor. Acid apatinib shows excellent efficacy and good tolerance for the advanced NSCLC whose multi-line treatment has been failed. This paper reports a case of apatinib mesylate as a fourth-line drug treatment in patients with advanced non-squamous NSCLC brain metastases.

祝金龙, 王红. 甲磺酸阿帕替尼治疗一例肺腺癌脑转移患者的疗效分析[J]. 亚洲肿瘤科病例研究, 2017, 6(1): 1-8.


[1] Mok, T., et al. (2014) A correlate Ⅳ Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemo Therapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer: Results of the Phase 2 Randomized ABIGAIL Study. Journal of Thoracic Oncology, 9, 848-55.
[2] Zhou, C., et al. (2015) BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients with Advanced or Recurrent NonSquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 33, 2197-2204.
[3] Reck, M., et al. (2014) Docetaxel Plus Nintedanib versus Docetaxel Plus Placebo in Patients with Previously Treated Non-Small-Cell Lung Cancer (LUME-Lung 1). A Phase 3, Double-Blind, Randomized Controlled Trial. Lancet Oncology, 15, 143-155.
[4] Seto, T., et al. (2014) Erlotinib Alone or with Bevacizumab as First-Line Therapy in Patients with Advanced Non-Squamous Non-Small-Cell-Lung Cancer Harbouring EGFR Mutations (J025567): An Open-Label Randomised, Multicentre, Phase 2 Study. Lancet Oncology, 15, 1236-1244.
[5] Sandler, A., et al. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 355, 2542-2550.
[6] Reck, M., et al. (2009) Phase 3 Trial of Cisplatin Plus Gemcitabine with Either Placebo or Bevarizumab as First-Line Therapy Fornonsquamous Non-Small-Cell Lung Cancer: AVAil. Journal of Clinical Oncology, 27, 1227-1234.
[7] Patel, J. D., et al. (2013) Point Break: A Randomized Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumah Followed by Maintenance Pemetrexed and Bevacizumah versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage 3 B or 4 Non-Squamousnon-Small-Cell Lung Cancer. Journal of Clinical Oncology, 31, 4349-4357.
[8] Garon, E.B., et al. (2014) Ramucirumab Plus Docetaxel versus Placebo Plus Docetaxel for Second-Line Treatment of Stage 4 Non-Small-Cell Lung Cancer after Disease Progression on Platinum-Based Therapy (REVEL): Amulti Centre, Double-Blind, Randomized Phase 3 Trial. Lancet, 384, 665-673.
[9] Barlesi, F., et al. (2013) Randomized Phase 3 Trial of Maintenance Bevacizumab with or without Pemetrexed after First-Line Induction with Bevacizumab, Cisplatin, and Pemetrexed Inadvanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (M022089). Journal of Clinical Oncology, 31, 3004-3011.
[10] Lynch, T.J., el al. (2014) Safety and Effect 4 Eness of Bevacizumab-Containing Treatment for Non-Small-Cell Lung Cancer : Final Results of the ARIES Observational Cohort Study. Journal of Thoracic Oncology, 9, 1332-1339.
[11] Crino, L., et al. (2010) Safety and Efficacy of First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (SAiL, M019390): A Phase 4 Study. Lancet Oncology, 11, 733-740.
[12] Heist, R.S., et al. (2008) VEGF Polymorphisms and Survival 4 in Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 856-862.